##  [FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer](/us-en/news/media-releases/fda-approves-novartis-drug-odomzo-sonidegib-locally-advanced-basal-cell-carcinoma-labcc-form-skin-cancer-0 "FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer") 

  Jul 24, 2015